GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.

US-based heart disease therapy developer Tenaya Therapeutics collected $106m yesterday in a series C round yesterday that included GV, a corporate venturing arm of technology conglomerate Alphabet. The round was led by investment firm RTW Investments and also featured investment and financial services group Fidelity, RA Capital Management, Column Group, Casdin Capital, funds and accounts…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.